Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular...
Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular...
Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions Significant unmet...
REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus...
Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for...
REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart Renovacor, Inc. (NYSE: RCOR), a...
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 0.0968992248062 | 20.64 | 20.66 | 20.51 | 45153 | 20.57877296 | CS |
4 | 0.08 | 0.388726919339 | 20.58 | 20.69 | 20.51 | 24467 | 20.58344417 | CS |
12 | -0.04 | -0.193236714976 | 20.7 | 20.98 | 20.46 | 31044 | 20.69076946 | CS |
26 | 0.52 | 2.5819265144 | 20.14 | 20.98 | 20.04 | 28936 | 20.52680865 | CS |
52 | 0.63 | 3.14528207688 | 20.03 | 20.98 | 19.85 | 27161 | 20.42248337 | CS |
156 | 0.63 | 3.14528207688 | 20.03 | 20.98 | 19.85 | 27161 | 20.42248337 | CS |
260 | 0.63 | 3.14528207688 | 20.03 | 20.98 | 19.85 | 27161 | 20.42248337 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관